Coronavirus vaccines are mRNA based vaccines is being developed by CureVac in collaboration with Coalition for Epidemic Preparedness Innovations by using Curevac's mRNA technology for the prevention of COVID-2019 infections. The vaccine uses The RNA Printer™ technology, that delivers mRNA directly into the cell, to be translated against specific viral protein/antigen to induce immune response. To prevent mRNA degradation and improve it effectiveness the mRNA is encapsulated into the lipid nanoparticles. The RNA Printer™ technology is capable of producing several grams of LNP-formulated mRNA within few weeks, making it cost effective and time saving compared to traditional vaccine platforms. Preclinical trial is underway in Germany.
In January 2020, CureVac and Coalition for Epidemic Preparedness Innovations (CEPI) extended their collaboration to develop vaccine against COVID-2019 infections. Initial funds up to $US8.3 miilion will be provided by CEPI to CureVac for the vaccine development, manufacturing and clinical tests. In February 2019, Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac entered into a partnership agreement worth upto $US34 million for The RNA Printer™ prototype to develop lipid-nanoparticle (LNP)-formulated mRNA vaccine candidates. Under the terms of the three-year partnership agreement, CureVac will use its mRNA plaform to undertake preclinical development of vaccine candidates against coronavirus infections, Lassa Fever (which is listed on the WHO’s R&D blueprint for priority diseases), Rabies, and Yellow Fever. Following successful preclinical tests for the three named indications, two of the vaccine candidates will undergo phase I clinical trials in humans.  
Key Development Milestones
In January 2020, CureVac launched pre-clinical tests with a variety of potential antigenic constructs based on the spike protein to elicit high immunogenicity. As of May 2020, in preclinical studies, vaccine showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses  .
A coronavirus vaccine received financial support from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation as well as from the Defense Advanced Research Projects Agency (DARPA), an agency of the US Department of Defense